4 March 2019 - - US-based commercial-stage pharmaceutical company Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV) has received approval from Health Canada to market its product Diabasens as a Natural Health Product, for the indication to relieve cutaneous pain associated with diabetic neuropathy, the company said.

The product will be available as an over-the-counter or behind the counter product and will not require a prescription.

Diabasens is a proprietary cream approved by Health Canada that relieves pain associated with diabetic neuropathy.

The product is also designed with specific ingredients to increase blood flow into the legs and feet and increase nerve sensation.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialisation, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases.

Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its OTC medicines and consumer and health products, which we market directly, commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through our on-line channels, retailers and wholesalers.

The company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application products.

The company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.